We assessed long-term outcome of 118 consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (IFN-α) in the Central and Northern Moravia region between 1989 and 2006 with focus on operational cure. The median follow-up was 82.6 months (range 12.4-212.6). Eighteen (15.3%) patients achieved complete cytogenetic response (CCyR) after median 16.7 (3.7-40.8) months. Nine of these patients (7.6%) achieved BCR-ABL negativity in nested reverse transcriptase-polymerase chain reaction ["complete" molecular response (CMR)] and 6 of them have been operationally cured without any treatment for median 6 (4-10) years, while 2 continue with IFN-α and 1 died from CML-unrelated cause. Operationally cured patients had a significantly lower percentage of initial peripheral promyelocytes, blasts, and erythroblasts than the rest of patients treated for more than 12 months (P=0.01-0.03). Unlike patients with sole CCyR, the majority of whom lost CCyR despite continuing IFN-α therapy and required imatinib, patients who achieved CMR had excellent long-term outcome.

Department of Hemato Oncology Faculty of Medicine and Dentistry Palacky University in Olomouc Olomouc Czech Republic

Zobrazit více v PubMed

Angstreich GR. Matsui W. Huff CA. Vala MS. Barber J. Hawkins AL. Griffin CA. Smith BD. Jones RJ. Effects of imatinib and interferon on primitive chronic myeloid leukemia progenitors. Br J Haematol. 2005;130(3):373–381. PubMed

Baccarani M. Cortes J. Pane F. Niederwieser D. Saglio G. Apperley J. Cervantes F. Deininger M. Gratwohl A. Guilhot F. Hochhaus A. Horowitz M. Hughes T. Kantarjian H. Larson R. Radich J. Simonsson B. Silver RT. Goldman J. Hehlmann R. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041–6051. PubMed PMC

Burchert A. Neubauer A. Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma. 2005;46(2):167–175. PubMed

Fialkow PJ. Gartler SM. Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci U S A. 1967;58(4):1468–1471. PubMed PMC

Gabert J. Beillard E. van der Velden VHJ. Bi W. Grimwade D. Pallisgaard N. Barbany G. Cazzaniga G. Cayuela JM. Cavé H. Pane F. Aerts JLE. De Micheli D. Thirion X. Pradel V. González M. Viehmann S. Malec M. Saglio G. van Dongen JJM. Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for rezidual disease detection in leukemia—a Europe Against Cancer Program. Leukemia. 2003;17(12):2318–2357. PubMed

Holyoake T. Jiang X. Eaves C. Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94(6):2056–2064. PubMed

Jiang G. Yang F. Li M. Weissbecker K. Price S. Kim KC. La Russa VF. Safah H. Ehrlich M. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes. Cancer Biol Ther. 2003;2(1):103–108. PubMed

Kantarjian HM. O'Brien S. Cortes JE. Shan J. Giles FJ. Rios MB. Faderl SH. Wierda WG. Ferrajoli A. Verstovsek S. Keating MJ. Freireich EJ. Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97(4):1033–1041. PubMed

Kaplan EL. Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.

Kreutzman A. Rohon P. Faber E. Indrak K. Juvonen V. Kairisto V. Voglova J. Sinisalo M. Flochova E. Vakkila J. Arstila P. Porkka K. Mustjoki S. Chronic myeloid leukemia patients in prolonged remission following interferon-a monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS ONE. 2011;6(8):e23022. PubMed PMC

Mahon FX. Delbrel X. Cony-Makhoul P. Faberes C. Boiron JM. Barthe C. Bilhou-Nabéra C. Pigneux A. Marit G. Reiffers J. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20(1):214–220. PubMed

Mahon FX. Fort MP. Etienne G. Marit G. Milpied N. Pigneux A. Cony-Makhoul P. Reiffers J. Interferon alpha alone is able to cure chronic myeloid leukemia in a small subset of patients despite the persistence of leukemic cells: experience of long follow up after treatment discontinuation. Blood. 2010;116(21) abstract 2299.

Pierce A. Smith DL. Jakobsen LV. Whetton AD. Spooncer E. The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells. Hematol J. 2001;2(4):257–264. PubMed

Preudhomme C. Guilhot J. Nicolini FE. Guerci-Bresler A. Rigal-Huguet F. Maloisel F. Coiteux V. Gardembas M. Berthou C. Vekhoff A. Rea D. Jourdan E. Allard C. Delmer A. Rousselot P. Legros L. Berger M. Corm S. Etienne G. Roche-Lestienne C. Eclache V. Mahon F-X. Guilhot F for the SPIRIT Investigators and France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC) Imatinib plus Peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511–2521. PubMed

Ross DM. Hughes TP. Melo JV. Do we have to kill the last CML cell? Leukemia. 2011;25(2):193–200. PubMed

Talpaz M. Kantarjian H. Kurzrock R. Trujillo JM. Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med. 1991;114(7):532–538. PubMed

van Dongen JJ. Macintyre EA. Gabert JA. Delabesse E. Rossi V. Saglio G. Gottardi E. Rambaldi A. Dotti G. Griesinger F. Parreira A. Gameiro P. González Diáz M. Malec M. Langerak AW. San Miguel JF. Biondi A. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901–1928. PubMed